Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?

Immunotherapy with gene engineered CAR and TCR transgenic T-cells is a transformative treatment in cancer medicine. There is a rich pipeline with target antigens and sophisticated technologies that will enable establishing this novel treatment not only in rare hematological malignancies, but also in...

Descripción completa

Detalles Bibliográficos
Autores principales: Guedan, Sonia, Luu, Maik, Ammar, Delphine, Barbao, Paula, Bonini, Chiara, Bousso, Philippe, Buchholz, Christian J, Casucci, Monica, De Angelis, Biagio, Donnadieu, Emmanuel, Espie, David, Greco, Beatrice, Groen, Richard, Huppa, Johannes B, Kantari-Mimoun, Chahrazade, Laugel, Bruno, Mantock, Mary, Markman, Janet L, Morris, Emma, Quintarelli, Concetta, Rade, Michael, Reiche, Kristin, Rodriguez-Garcia, Alba, Rodriguez-Madoz, Juan Roberto, Ruggiero, Eliana, Themeli, Maria, Hudecek, Michael, Marchiq, Ibtissam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115015/
https://www.ncbi.nlm.nih.gov/pubmed/35577501
http://dx.doi.org/10.1136/jitc-2021-003487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115015/
https://www.ncbi.nlm.nih.gov/pubmed/35577501
http://dx.doi.org/10.1136/jitc-2021-003487

Ejemplares similares